Zobrazeno 1 - 10
of 22
pro vyhledávání: '"G D, Novack"'
Autor:
G. D. Novack
Publikováno v:
Clinical Pharmacology & Therapeutics. 85:539-543
This review presents an update on the development of ophthalmic drug delivery systems (Table 1), as well as regulatory aspects of product development. This review is based on full papers and published patents as of November 2008. Clinical Pharmacolog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6a5d7a9f34727bb226109b8f0950d7e3
https://doi.org/10.1038/clpt.2008.297
https://doi.org/10.1038/clpt.2008.297
Autor:
G D, Novack, R S, Crockett
Publikováno v:
Archives of ophthalmology (Chicago, Ill. : 1960). 118(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1f21a5cabc1b608bc5d716981b0513a9
https://pubmed.ncbi.nlm.nih.gov/11296039
https://pubmed.ncbi.nlm.nih.gov/11296039
Autor:
G D, Novack
Publikováno v:
Investigative ophthalmologyvisual science. 40(12)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3f61375e8bc033b8a20e21a030bc5f66
https://pubmed.ncbi.nlm.nih.gov/10549632
https://pubmed.ncbi.nlm.nih.gov/10549632
Publikováno v:
Ophthalmology. 106(2)
To evaluate the effects of loteprednol etabonate (LE) 0.2% in reducing the signs and symptoms of seasonal allergic conjunctivitis.Randomized, double-masked, placebo-controlled, parallel group multicenter study of 6 weeks duration.A total of 135 patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::7fc13600bee4edb61d22fb1fe95bb6e8
https://pubmed.ncbi.nlm.nih.gov/9951491
https://pubmed.ncbi.nlm.nih.gov/9951491
Publikováno v:
Journal of cataract and refractive surgery. 24(11)
To compare the efficacy and safety of loteprednol etabonate 0.5% with those of a placebo (vehicle) in controlling anterior chamber cell and flare reaction in patients having cataract surgery with intraocular lens (IOL) implantation.This randomized, d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::8adeec52b6e0588769edb63888d8ba5d
https://pubmed.ncbi.nlm.nih.gov/9818338
https://pubmed.ncbi.nlm.nih.gov/9818338
Publikováno v:
Journal of glaucoma. 7(4)
Loteprednol etabonate is a novel site-active corticosteroid synthesized through structural modifications of prednisolone-related compounds so that it will undergo a predictable transformation to an inactive metabolite. In double-masked studies, lotep
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::5d2062b791af0bfd06a6499d78afc553
https://pubmed.ncbi.nlm.nih.gov/9713785
https://pubmed.ncbi.nlm.nih.gov/9713785
Autor:
G D, Novack
Publikováno v:
Journal of glaucoma. 7(3)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::ece868ce42df972af469de74b244bc59
https://pubmed.ncbi.nlm.nih.gov/9627860
https://pubmed.ncbi.nlm.nih.gov/9627860
Publikováno v:
Journal of glaucoma. 6(1)
This study was performed to determine the effect of duration of mitomycin exposure during trabeculectomy surgery on filtration success in eyes that had and had not been subjected to previous surgery.On hundred six eyes of 92 patients were retrospecti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9bee6c4da8f5c2d7655108173973f769
https://pubmed.ncbi.nlm.nih.gov/9075073
https://pubmed.ncbi.nlm.nih.gov/9075073
Autor:
R J, Derick, A L, Robin, J, Tielsch, J L, Wexler, E P, Kelley, J F, Stoecker, G D, Novack, A L, Coleman
Publikováno v:
Ophthalmology. 99(3)
The authors executed a two-period, randomized, double-masked, crossover study comparing once-daily to twice-daily levobunolol hydrochloride (0.5%) in 20 patients with elevated intraocular pressure (IOP). Modified diurnal curves were performed at four
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b1f25e2077e8db7071e99831add4a2e5
https://pubmed.ncbi.nlm.nih.gov/1565455
https://pubmed.ncbi.nlm.nih.gov/1565455
Autor:
G. D. Novack
Publikováno v:
Clinical Pharmacology & Therapeutics. 73:P64-P64
● CONCLUSIONS: Quality filings currently appear to be reviewed and approved in 1 year or less. Because of the confidential nature of corporate development, no analysis can be made regarding changes in the presubmission costs and timing. (Am J Ophth
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3393dda7a85aaa55a9d73a8b2f14e5bf
https://doi.org/10.1016/s0009-9236(03)90593-5
https://doi.org/10.1016/s0009-9236(03)90593-5